NSG 552: ADVANCED PSYCHOPHARMACOLOGY
COMPREHENSIVE EXAM BUNDLE (EXAMS 1–3)
200 Practice Examination Questions with Detailed Clinical Rationales
Wilkes University Advanced Practice Nursing Curriculum
SECTION I: EXAM 1 — NEUROBIOLOGY,
PHARMACOKINETICS & ANTIDEPRESSANTS (QUESTIONS
1–67)
Question 1: A 42-year-old patient with major depressive disorder
and chronic neuropathic pain is initiated on duloxetine. Which
mechanism accounts for its dual efficacy in mood and pain?
A) Selective inhibition of central histamine H1 receptors
B) Simultaneous inhibition of serotonin and norepinephrine reuptake
transporters in descending pain modulatory pathways
C) Direct blockade of N-methyl-D-aspartate (NMDA) glutamate
receptors
D) Agonism at central mu-opioid receptors
Correct Answer: B
Clinical Rationale: Duloxetine is an SNRI where dual reuptake
inhibition of serotonin and norepinephrine enhances descending
inhibitory pain pathways in the spinal cord, making it effective for
both depression and chronic pain conditions like diabetic neuropathy
or fibromyalgia.
Question 2: A psychiatric-mental health nurse practitioner is
evaluating a patient with treatment-resistant depression who is
prescribed citalopram 60 mg daily. Which safety warning regarding
high-dose citalopram must the clinician consider?
, A) Risk of severe agranulocytosis requiring weekly CBC monitoring
B) Risk of dose-dependent QTc interval prolongation leading to
torsades de pointes
C) Permanent extrapyramidal symptoms and tardive dyskinesia
D) Severe acute hepatic failure within 48 hours of initiation
Correct Answer: B
Clinical Rationale: The FDA issued warnings regarding citalopram
doses exceeding 40 mg/day (or 20 mg/day in elderly or CYP2C19
poor metabolizers) due to dose-dependent QTc prolongation,
necessitating baseline and follow-up ECG monitoring.
Question 3: A patient started on escitalopram reports sexual
dysfunction, including delayed orgasm and decreased libido. What
is the underlying pharmacodynamic cause of this adverse effect?
A) Excessive stimulation of postsynaptic serotonin 5-HT2 and 5-HT3
receptors in spinal reflex arcs
B) Antagonism of central dopamine D2 receptors in the
tuberoinfundibular pathway
C) Blockade of peripheral alpha-1 adrenergic receptors causing
vasoconstriction
D) Inhibition of acetylcholine synthesis in the neuromuscular junction
Correct Answer: A
Clinical Rationale: SSRI-induced sexual dysfunction is primarily
mediated by excessive serotonin tone at 5-HT2 and 5-HT3 receptors,
which inhibits nitric oxide synthase, reduces dopamine release in
reward centers, and delays spinal orgasm reflexes.
,Question 4: Which antidepressant class requires strict avoidance of
tyramine-containing foods due to irreversible inhibition of intestinal
MAO-A enzymes?
A) Selective Serotonin Reuptake Inhibitors (SSRIs)
B) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
C) Monoamine Oxidase Inhibitors (MAOIs)
D) Atypical Antidepressants (e.g., bupropion)
Correct Answer: C
Clinical Rationale: Irreversible non-selective MAOIs (e.g.,
tranylcypromine, phenelzine) inhibit monoamine oxidase A in the gut
wall and liver. Failure to restrict dietary tyramine leads to systemic
accumulation, sympathetic nerve displacement of norepinephrine,
and hypertensive crisis.
Question 5: A patient taking bupropion for major depressive
disorder asks why they do not experience sexual side effects
common with SSRIs. What is the unique pharmacological profile of
bupropion?
A) It acts as a potent serotonin 5-HT1A partial agonist
B) It functions as a norepinephrine-dopamine reuptake inhibitor
(NDRI) with no direct serotonergic activity
C) It directly stimulates central GABA-B receptors
D) It irreversibly blocks monoamine oxidase B
Correct Answer: B
Clinical Rationale: Bupropion inhibits norepinephrine and
dopamine reuptake without significant serotonergic activity. Because
, sexual side effects are driven by serotonin, bupropion is frequently
chosen as first-line or adjunctive therapy to avoid sexual dysfunction.
Question 6: A 42-year-old patient with major depressive disorder
and chronic neuropathic pain is initiated on duloxetine. Which
mechanism accounts for its dual efficacy in mood and pain?
A) Selective inhibition of central histamine H1 receptors
B) Simultaneous inhibition of serotonin and norepinephrine reuptake
transporters in descending pain modulatory pathways
C) Direct blockade of N-methyl-D-aspartate (NMDA) glutamate
receptors
D) Agonism at central mu-opioid receptors
Correct Answer: B
Clinical Rationale: Duloxetine is an SNRI where dual reuptake
inhibition of serotonin and norepinephrine enhances descending
inhibitory pain pathways in the spinal cord, making it effective for
both depression and chronic pain conditions like diabetic neuropathy
or fibromyalgia.
Question 7: A psychiatric-mental health nurse practitioner is
evaluating a patient with treatment-resistant depression who is
prescribed citalopram 60 mg daily. Which safety warning regarding
high-dose citalopram must the clinician consider?
A) Risk of severe agranulocytosis requiring weekly CBC monitoring
B) Risk of dose-dependent QTc interval prolongation leading to
torsades de pointes
C) Permanent extrapyramidal symptoms and tardive dyskinesia
COMPREHENSIVE EXAM BUNDLE (EXAMS 1–3)
200 Practice Examination Questions with Detailed Clinical Rationales
Wilkes University Advanced Practice Nursing Curriculum
SECTION I: EXAM 1 — NEUROBIOLOGY,
PHARMACOKINETICS & ANTIDEPRESSANTS (QUESTIONS
1–67)
Question 1: A 42-year-old patient with major depressive disorder
and chronic neuropathic pain is initiated on duloxetine. Which
mechanism accounts for its dual efficacy in mood and pain?
A) Selective inhibition of central histamine H1 receptors
B) Simultaneous inhibition of serotonin and norepinephrine reuptake
transporters in descending pain modulatory pathways
C) Direct blockade of N-methyl-D-aspartate (NMDA) glutamate
receptors
D) Agonism at central mu-opioid receptors
Correct Answer: B
Clinical Rationale: Duloxetine is an SNRI where dual reuptake
inhibition of serotonin and norepinephrine enhances descending
inhibitory pain pathways in the spinal cord, making it effective for
both depression and chronic pain conditions like diabetic neuropathy
or fibromyalgia.
Question 2: A psychiatric-mental health nurse practitioner is
evaluating a patient with treatment-resistant depression who is
prescribed citalopram 60 mg daily. Which safety warning regarding
high-dose citalopram must the clinician consider?
, A) Risk of severe agranulocytosis requiring weekly CBC monitoring
B) Risk of dose-dependent QTc interval prolongation leading to
torsades de pointes
C) Permanent extrapyramidal symptoms and tardive dyskinesia
D) Severe acute hepatic failure within 48 hours of initiation
Correct Answer: B
Clinical Rationale: The FDA issued warnings regarding citalopram
doses exceeding 40 mg/day (or 20 mg/day in elderly or CYP2C19
poor metabolizers) due to dose-dependent QTc prolongation,
necessitating baseline and follow-up ECG monitoring.
Question 3: A patient started on escitalopram reports sexual
dysfunction, including delayed orgasm and decreased libido. What
is the underlying pharmacodynamic cause of this adverse effect?
A) Excessive stimulation of postsynaptic serotonin 5-HT2 and 5-HT3
receptors in spinal reflex arcs
B) Antagonism of central dopamine D2 receptors in the
tuberoinfundibular pathway
C) Blockade of peripheral alpha-1 adrenergic receptors causing
vasoconstriction
D) Inhibition of acetylcholine synthesis in the neuromuscular junction
Correct Answer: A
Clinical Rationale: SSRI-induced sexual dysfunction is primarily
mediated by excessive serotonin tone at 5-HT2 and 5-HT3 receptors,
which inhibits nitric oxide synthase, reduces dopamine release in
reward centers, and delays spinal orgasm reflexes.
,Question 4: Which antidepressant class requires strict avoidance of
tyramine-containing foods due to irreversible inhibition of intestinal
MAO-A enzymes?
A) Selective Serotonin Reuptake Inhibitors (SSRIs)
B) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
C) Monoamine Oxidase Inhibitors (MAOIs)
D) Atypical Antidepressants (e.g., bupropion)
Correct Answer: C
Clinical Rationale: Irreversible non-selective MAOIs (e.g.,
tranylcypromine, phenelzine) inhibit monoamine oxidase A in the gut
wall and liver. Failure to restrict dietary tyramine leads to systemic
accumulation, sympathetic nerve displacement of norepinephrine,
and hypertensive crisis.
Question 5: A patient taking bupropion for major depressive
disorder asks why they do not experience sexual side effects
common with SSRIs. What is the unique pharmacological profile of
bupropion?
A) It acts as a potent serotonin 5-HT1A partial agonist
B) It functions as a norepinephrine-dopamine reuptake inhibitor
(NDRI) with no direct serotonergic activity
C) It directly stimulates central GABA-B receptors
D) It irreversibly blocks monoamine oxidase B
Correct Answer: B
Clinical Rationale: Bupropion inhibits norepinephrine and
dopamine reuptake without significant serotonergic activity. Because
, sexual side effects are driven by serotonin, bupropion is frequently
chosen as first-line or adjunctive therapy to avoid sexual dysfunction.
Question 6: A 42-year-old patient with major depressive disorder
and chronic neuropathic pain is initiated on duloxetine. Which
mechanism accounts for its dual efficacy in mood and pain?
A) Selective inhibition of central histamine H1 receptors
B) Simultaneous inhibition of serotonin and norepinephrine reuptake
transporters in descending pain modulatory pathways
C) Direct blockade of N-methyl-D-aspartate (NMDA) glutamate
receptors
D) Agonism at central mu-opioid receptors
Correct Answer: B
Clinical Rationale: Duloxetine is an SNRI where dual reuptake
inhibition of serotonin and norepinephrine enhances descending
inhibitory pain pathways in the spinal cord, making it effective for
both depression and chronic pain conditions like diabetic neuropathy
or fibromyalgia.
Question 7: A psychiatric-mental health nurse practitioner is
evaluating a patient with treatment-resistant depression who is
prescribed citalopram 60 mg daily. Which safety warning regarding
high-dose citalopram must the clinician consider?
A) Risk of severe agranulocytosis requiring weekly CBC monitoring
B) Risk of dose-dependent QTc interval prolongation leading to
torsades de pointes
C) Permanent extrapyramidal symptoms and tardive dyskinesia
